# Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma

> **NCT00268983** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 14 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **BIOLOGICAL:** Tositumomab and Iodine I 131 Tositumomab
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT00268983
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2009-09
- **Final completion:** 2013-06
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00268983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00268983, "Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00268983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*